Table 3.
Association between Patient Characteristics and Membership into Latent Classes of Adherence to Warfarin
| Late initiators (Class 1) n=980 | Early initiators discontinuing at months 1–3 (Class 2) n=1,297 | Early initiators discontinuing at months 5–10 (Class 3) n=735 | Continuously adherent users (Class 4) n=4,479 | P-valuea | |
|---|---|---|---|---|---|
| Age | 1.00 (0.99, 1.01) | 1.00 (0.99, 1.01) | 1.00 (0.99, 1.01) | 1 | 0.98 |
| Male | 0.75 (0.64, 0.88) | 0.91 (0.79, 1.05) | 1.04 (0.87, 1.24) | 1 | 0.002a |
| Race | 0.04 | ||||
| White | ref | ref | ref | ref | |
| Black | 0.93 (0.71, 1.20) | 1.28 (1.03, 1.61) | 1.08 (0.80, 1.46) | 1 | |
| Other | 0.94 (0.65, 1.36) | 1.42 (1.06, 1.92) | 1.45 (1.00, 2.09) | 1 | |
| Medicaid | 1.16 (0.92, 1.48) | 0.82 (0.66, 1.01) | 1.94 (1.38, 2.70) | 1 | <0.001a |
| Income Subsidy | 1.11 (0.89, 1.38) | 1.31 (1.09, 1.59) | 0.50 (0.37, 0.69) | 1 | <0.001a |
| SES | 1.00 (0.92, 1.08) | 1.05 (0.98, 1.12) | 1.04 (0.95, 1.13) | 1 | 0.56 |
| Dissimilarity | 1.17 (0.76, 1.81) | 1.43 (0.97, 2.11) | 2.03 (1.24, 3.30) | 1 | 0.02 |
| Rural | 0.87 (0.73, 1.03) | 0.98 (0.84, 1.14) | 0.98 (0.81, 1.19) | 1 | 0.44 |
| Region | 0.002a | ||||
| Midwest | 0.95 (0.78, 1.14) | 0.76 (0.64, 0.91) | 0.97 (0.78, 1.21) | 1 | |
| Northeast | ref | ref | ref | ||
| Southeast | 1.04 (0.84, 1.28) | 1.09 (0.90, 1.31) | 1.10 (0.87, 1.41) | 1 | |
| Southwest | 1.08 (0.79, 1.47) | 1.30 (1.00, 1.70) | 1.18 (0.83, 1.69) | 1 | |
| West | 0.98 (0.76, 1.27) | 1.15 (0.92, 1.43) | 1.36 (1.03, 1.79) | 1 | |
| CHA2DS2-VAScc | 0.95 (0.89, 1.01) | 0.92 (0.87, 0.97) | 1.06 (0.99, 1.14) | 1 | <0.001a |
| HAS-BLEDc | 1.21 (1.10, 1.33) | 1.10 (1.01, 1.20) | 0.98 (0.88, 1.10) | 1 | <0.001a |
| AD or Dementiac | 1.16 (0.97, 1.40) | 1.23 (1.04, 1.46) | 1.05 (0.84, 1.31) | 1 | 0.08 |
| NSAID or Antiplatelet Usec | 1.01 (0.84, 1.21) | 1.02 (0.87, 1.21) | 1.11 (0.90, 1.21) | 1 | 0.83 |
| Antiarrhythmic Medication Useb, c | 0.72 (0.53, 0.98) | 1.29 (1.03, 1.61) | 1.13 (0.85, 1.51) | 1 | 0.008 |
Abbreviations: SES: social economic status; AD: Alzheimer’s disease; NSAID, nonsteroidal anti-inflammatory drugs;
a.
Results were statistically significant after the Holm modified Bonferroni correction;
b.
Antiarrhythmic medications included amiodarone, dronaderone, and verapamil;
c.
Clinical characteristics were defined based on 12 months of claims data prior to AF diagnosis.